Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Impact of adiponectin overexpression on allergic airways responses in mice.

Journal of allergy

Verbout NG, Benedito L, Williams AS, Kasahara DI, Wurmbrand AP, Si H, Halayko AJ, Hug C, Shore SA.
PMID: 23861690
J Allergy (Cairo). 2013;2013:349520. doi: 10.1155/2013/349520. Epub 2013 Jun 04.

Obesity is an important risk factor for asthma. Obese individuals have decreased circulating adiponectin, an adipose-derived hormone with anti-inflammatory properties. We hypothesized that transgenic overexpression of adiponectin would attenuate allergic airways inflammation and mucous hyperplasia in mice. To test...

Cite
Verbout NG, Benedito L, Williams AS, et al. Impact of adiponectin overexpression on allergic airways responses in mice. J Allergy (Cairo). 2013;2013:349520doi: 10.1155/2013/349520.
Verbout, N. G., Benedito, L., Williams, A. S., Kasahara, D. I., Wurmbrand, A. P., Si, H., Halayko, A. J., Hug, C., & Shore, S. A. (2013). Impact of adiponectin overexpression on allergic airways responses in mice. Journal of allergy, 2013349520. https://doi.org/10.1155/2013/349520
Verbout, Norah G, et al. "Impact of adiponectin overexpression on allergic airways responses in mice." Journal of allergy vol. 2013 (2013): 349520. doi: https://doi.org/10.1155/2013/349520
Verbout NG, Benedito L, Williams AS, Kasahara DI, Wurmbrand AP, Si H, Halayko AJ, Hug C, Shore SA. Impact of adiponectin overexpression on allergic airways responses in mice. J Allergy (Cairo). 2013;2013:349520. doi: 10.1155/2013/349520. Epub 2013 Jun 04. PMID: 23861690; PMCID: PMC3686156.
Copy Download .nbib Format: NLM
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Blood

Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A.
PMID: 34086880
Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725.

End-stage renal disease (ESRD) patients on chronic hemodialysis have repeated blood exposure to artificial surfaces that can trigger clot formation within the hemodialysis circuit. Dialyzer clotting can lead to anemia despite erythropoietin and iron supplementation. Unfractionated heparin prevents clotting...

Cite
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173-2184doi: 10.1182/blood.2021011725.
Lorentz, C. U., Tucker, E. I., Verbout, N. G., Shatzel, J. J., Olson, S. R., Markway, B. D., Wallisch, M., Ralle, M., Hinds, M. T., McCarty, O. J. T., Gailani, D., Weitz, J. I., & Gruber, A. (2021). The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 138(22), 2173-2184. https://doi.org/10.1182/blood.2021011725
Lorentz, Christina U, et al. "The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial." Blood vol. 138,22 (2021): 2173-2184. doi: https://doi.org/10.1182/blood.2021011725
Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725. PMID: 34086880; PMCID: PMC8641100.
Copy Download .nbib Format: NLM
The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials.

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie

Vogelyl HC, Dhertl WJ, Fleer A, Verboutl AJ.
PMID: 24193671
Eur J Orthop Surg Traumatol. 1996 May;6(2):91-5. doi: 10.1007/BF00568319.

There is a lack in basic and clinical knowledge on the pathogenesis of orthopaedic implant infections, particularly as a sequel of a bacteremia. In the present study an experimental animal model was developed, that allows us to study haematogenous...

Cite
Vogelyl HC, Dhertl WJ, Fleer A, et al. L'implant orthopédique infecté. Un modèle animal pour étudier les mécanismes d'infection hématogénique de matériel d'implant sans ciment. The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials. Eur J Orthop Surg Traumatol. 1996;6(2):91-5doi: 10.1007/BF00568319.
Vogelyl, H. C., Dhertl, W. J., Fleer, A., & Verboutl, A. J. (1996). L'implant orthopédique infecté. Un modèle animal pour étudier les mécanismes d'infection hématogénique de matériel d'implant sans ciment. The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 6(2), 91-5. https://doi.org/10.1007/BF00568319
Vogelyl, H C, et al. "L'implant orthopédique infecté. Un modèle animal pour étudier les mécanismes d'infection hématogénique de matériel d'implant sans ciment." The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie vol. 6,2 (1996): 91-5. doi: https://doi.org/10.1007/BF00568319
Vogelyl HC, Dhertl WJ, Fleer A, Verboutl AJ. L'implant orthopédique infecté. Un modèle animal pour étudier les mécanismes d'infection hématogénique de matériel d'implant sans ciment. The infected orthopaedic implant. An animal model to study the mechanisms of haematogenous infection of cementless implant materials. Eur J Orthop Surg Traumatol. 1996 May;6(2):91-5. doi: 10.1007/BF00568319. PMID: 24193671.
Copy Download .nbib Format: NLM
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Blood

Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A.
PMID: 34086880
Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725.

End-stage renal disease (ESRD) patients on chronic hemodialysis have repeated blood exposure to artificial surfaces that can trigger clot formation within the hemodialysis circuit. Dialyzer clotting can lead to anemia despite erythropoietin and iron supplementation. Unfractionated heparin prevents clotting...

Cite
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173-2184doi: 10.1182/blood.2021011725.
Lorentz, C. U., Tucker, E. I., Verbout, N. G., Shatzel, J. J., Olson, S. R., Markway, B. D., Wallisch, M., Ralle, M., Hinds, M. T., McCarty, O. J. T., Gailani, D., Weitz, J. I., & Gruber, A. (2021). The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 138(22), 2173-2184. https://doi.org/10.1182/blood.2021011725
Lorentz, Christina U, et al. "The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial." Blood vol. 138,22 (2021): 2173-2184. doi: https://doi.org/10.1182/blood.2021011725
Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725. PMID: 34086880; PMCID: PMC8641100.
Copy Download .nbib Format: NLM
Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits.

Journal of materials science. Materials in medicine

Nijhof MW, Dhert WJ, Tilman PB, Verbout AJ, Fleer A.
PMID: 15348794
J Mater Sci Mater Med. 1997 Dec;8(12):799-802. doi: 10.1023/a:1018577032259.

Tobramycin release from tobramycin-containing bone cement was studied in vivo in a rabbit model. After insertion of cement into the right femur, tobramycin concentration as a function of time for up to 28 days was measured in serum and...

Cite
Nijhof MW, Dhert WJ, Tilman PB, et al. Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits. J Mater Sci Mater Med. 1997;8(12):799-802doi: 10.1023/a:1018577032259.
Nijhof, M. W., Dhert, W. J., Tilman, P. B., Verbout, A. J., & Fleer, A. (1997). Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits. Journal of materials science. Materials in medicine, 8(12), 799-802. https://doi.org/10.1023/a:1018577032259
Nijhof, M W, et al. "Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits." Journal of materials science. Materials in medicine vol. 8,12 (1997): 799-802. doi: https://doi.org/10.1023/a:1018577032259
Nijhof MW, Dhert WJ, Tilman PB, Verbout AJ, Fleer A. Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits. J Mater Sci Mater Med. 1997 Dec;8(12):799-802. doi: 10.1023/a:1018577032259. PMID: 15348794.
Copy Download .nbib Format: NLM
Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice.

Translational stroke research

Leung PY, Hurst S, Berny-Lang MA, Verbout NG, Gailani D, Tucker EI, Wang RK, McCarty OJ, Gruber A.
PMID: 23634198
Transl Stroke Res. 2012 Sep;3(3):381-9. doi: 10.1007/s12975-012-0186-5.

Blood coagulation factor XI (FXI) is an established risk factor for acute ischemic stroke (AIS) and thrombosis, but is also needed for normal hemostasis. Contact factor XII (FXII), an upstream activator of FXI, also contributes to experimental stroke, but...

Cite
Leung PY, Hurst S, Berny-Lang MA, et al. Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Transl Stroke Res. 2012;3(3):381-9doi: 10.1007/s12975-012-0186-5.
Leung, P. Y., Hurst, S., Berny-Lang, M. A., Verbout, N. G., Gailani, D., Tucker, E. I., Wang, R. K., McCarty, O. J., & Gruber, A. (2012). Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Translational stroke research, 3(3), 381-9. https://doi.org/10.1007/s12975-012-0186-5
Leung, Philberta Y, et al. "Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice." Translational stroke research vol. 3,3 (2012): 381-9. doi: https://doi.org/10.1007/s12975-012-0186-5
Leung PY, Hurst S, Berny-Lang MA, Verbout NG, Gailani D, Tucker EI, Wang RK, McCarty OJ, Gruber A. Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. Transl Stroke Res. 2012 Sep;3(3):381-9. doi: 10.1007/s12975-012-0186-5. PMID: 23634198; PMCID: PMC3637928.
Copy Download .nbib Format: NLM
Evaluating 3D bone tissue engineered constructs with different seeding densities using the alamarBlue assay and the effect on in vivo bone formation.

Journal of materials science. Materials in medicine

Wilson CE, Dhert WJ, Van Blitterswijk CA, Verbout AJ, De Bruijn JD.
PMID: 15348675
J Mater Sci Mater Med. 2002 Dec;13(12):1265-9. doi: 10.1023/a:1021139415528.

Bone tissue engineering using patient derived cells seeded onto porous scaffolds has gained much attention in recent years. Evaluating the viability of these 3D constructs is an essential step in optimizing the process. The alamarBlue (aB) assay was evaluated...

Cite
Wilson CE, Dhert WJ, Van Blitterswijk CA, et al. Evaluating 3D bone tissue engineered constructs with different seeding densities using the alamarBlue assay and the effect on in vivo bone formation. J Mater Sci Mater Med. 2002;13(12):1265-9doi: 10.1023/a:1021139415528.
Wilson, C. E., Dhert, W. J., Van Blitterswijk, C. A., Verbout, A. J., & De Bruijn, J. D. (2002). Evaluating 3D bone tissue engineered constructs with different seeding densities using the alamarBlue assay and the effect on in vivo bone formation. Journal of materials science. Materials in medicine, 13(12), 1265-9. https://doi.org/10.1023/a:1021139415528
Wilson, C E, et al. "Evaluating 3D bone tissue engineered constructs with different seeding densities using the alamarBlue assay and the effect on in vivo bone formation." Journal of materials science. Materials in medicine vol. 13,12 (2002): 1265-9. doi: https://doi.org/10.1023/a:1021139415528
Wilson CE, Dhert WJ, Van Blitterswijk CA, Verbout AJ, De Bruijn JD. Evaluating 3D bone tissue engineered constructs with different seeding densities using the alamarBlue assay and the effect on in vivo bone formation. J Mater Sci Mater Med. 2002 Dec;13(12):1265-9. doi: 10.1023/a:1021139415528. PMID: 15348675.
Copy Download .nbib Format: NLM
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Blood

Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A.
PMID: 34086880
Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725.

End-stage renal disease (ESRD) patients on chronic hemodialysis have repeated blood exposure to artificial surfaces that can trigger clot formation within the hemodialysis circuit. Dialyzer clotting can lead to anemia despite erythropoietin and iron supplementation. Unfractionated heparin prevents clotting...

Cite
Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173-2184doi: 10.1182/blood.2021011725.
Lorentz, C. U., Tucker, E. I., Verbout, N. G., Shatzel, J. J., Olson, S. R., Markway, B. D., Wallisch, M., Ralle, M., Hinds, M. T., McCarty, O. J. T., Gailani, D., Weitz, J. I., & Gruber, A. (2021). The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood, 138(22), 2173-2184. https://doi.org/10.1182/blood.2021011725
Lorentz, Christina U, et al. "The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial." Blood vol. 138,22 (2021): 2173-2184. doi: https://doi.org/10.1182/blood.2021011725
Lorentz CU, Tucker EI, Verbout NG, Shatzel JJ, Olson SR, Markway BD, Wallisch M, Ralle M, Hinds MT, McCarty OJT, Gailani D, Weitz JI, Gruber A. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021 Dec 02;138(22):2173-2184. doi: 10.1182/blood.2021011725. PMID: 34086880; PMCID: PMC8641100.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries